These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 15245811)
1. DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. Tinzl M; Marberger M; Horvath S; Chypre C Eur Urol; 2004 Aug; 46(2):182-6; discussion 187. PubMed ID: 15245811 [TBL] [Abstract][Full Text] [Related]
2. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159 [TBL] [Abstract][Full Text] [Related]
3. PCA3: a molecular urine assay for predicting prostate biopsy outcome. Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257 [TBL] [Abstract][Full Text] [Related]
4. uPM3, a new molecular urine test for the detection of prostate cancer. Fradet Y; Saad F; Aprikian A; Dessureault J; Elhilali M; Trudel C; Mâsse B; Piché L; Chypre C Urology; 2004 Aug; 64(2):311-5; discussion 315-6. PubMed ID: 15302485 [TBL] [Abstract][Full Text] [Related]
5. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. de Kok JB; Verhaegh GW; Roelofs RW; Hessels D; Kiemeney LA; Aalders TW; Swinkels DW; Schalken JA Cancer Res; 2002 May; 62(9):2695-8. PubMed ID: 11980670 [TBL] [Abstract][Full Text] [Related]
6. [Detection of urine DD3/PSA mRNA ratio by duplex TaqMan RT-PCR assay and evolution of its primary application]. Chen FP; Chen LL; Shen M; Chen W; Tao ZH; Wu XL; Hu YP; Li CD; Chen ZG; Chen XD Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):261-4. PubMed ID: 18361839 [TBL] [Abstract][Full Text] [Related]
7. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Shappell SB; Fulmer J; Arguello D; Wright BS; Oppenheimer JR; Putzi MJ Urology; 2009 Feb; 73(2):363-8. PubMed ID: 18995890 [TBL] [Abstract][Full Text] [Related]
9. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487 [TBL] [Abstract][Full Text] [Related]
10. UPM3: review of a new molecular diagnostic urine test for prostate cancer. Saad F Can J Urol; 2005 Feb; 12 Suppl 1():40-3; discussion 99-100. PubMed ID: 15780164 [TBL] [Abstract][Full Text] [Related]
11. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888 [TBL] [Abstract][Full Text] [Related]
12. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209 [TBL] [Abstract][Full Text] [Related]
14. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398 [TBL] [Abstract][Full Text] [Related]
15. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322 [TBL] [Abstract][Full Text] [Related]
16. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644 [TBL] [Abstract][Full Text] [Related]
17. [Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction]. Tao ZH; Mao XL; Wang CH; Chen XD; Yu KY; Weng ZL; Hu YP; Zhang XH; Xie H; Wang OC; Song QT; Li CD; Chen ZG Zhonghua Nan Ke Xue; 2007 Feb; 13(2):130-3. PubMed ID: 17345768 [TBL] [Abstract][Full Text] [Related]
18. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580 [TBL] [Abstract][Full Text] [Related]
19. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Sokoll LJ; Ellis W; Lange P; Noteboom J; Elliott DJ; Deras IL; Blase A; Koo S; Sarno M; Rittenhouse H; Groskopf J; Vessella RL Clin Chim Acta; 2008 Mar; 389(1-2):1-6. PubMed ID: 18061575 [TBL] [Abstract][Full Text] [Related]
20. Progensa™ PCA3 test for prostate cancer. Durand X; Moutereau S; Xylinas E; de la Taille A Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]